The introduction of the ICR Registered Membership Examination is an exciting new move for ICR, allowing Affiliate Members of ICR who do not meet the academic requirement to become a Registered Member (RICR).
The introduction of the ICR Registered Membership Examination is an exciting new move for ICR, allowing Affiliate Members of ICR who do not meet the academic requirement to become a Registered Member (RICR). The examination has been designed not only to allow candidates to demonstrate their clinical research knowledge but also the application of that knowledge. The examination is also a method of formal assessment that can be used as a follow up to a learning programme.
The examination is in two parts, which can be taken at different times. The content of the Certificate (Paper I) tests the candidate's broad overview of the essential aspects of clinical research and the Diploma (Paper II) tests the candidate's ability to apply that knowledge. The examination has also been designed to cover areas of medical device clinical trials.
The examination has been prepared by a group of individuals from blue chip pharmaceutical companies, Clinical Research Organisations, study sites, data management/statistical and device companies. Registered Member of ICR (RICR) To become a Registered Member of the Institute of Clinical Research there are three distinct routes:
Benefits of the exam
There are several benefits of taking the examination. The examination is a professional recognition of an individual's experience and achievements amongst peers in the clinical research community. Individuals who pass both parts of the examination and who have completed one year's experience in a clinical research role, will become Registered Members (RICR). As a Registered Member (RICR), individuals can access members only pages on The Institute website, receive voting rights and take part in Institute wide activities. The examination is also open to all Institute members providing them with a certificate to demonstrate their knowledge of clinical research.
The examination will have to be taken at one of the recognised examination centres on the dates determined by ICR. The location of such centres will be dependant on numbers of candidates. Arrangements can be made for non-UK candidates so that they can sit the exam in their home country. The exam will be held twice per year, in April and October.
For more information about the ICR Registered Member Examination, a guidance document is available on our website to download. Individuals are also able to download a registration form for the examination. Candidates are encouraged to complete and return a self-assessment form in the first instance. We will be accepting applications from 30 June onwards. The cut-off date for applications is 30 September. ABOUT THE INSTITUTE OF CLINICAL RESEARCH
To be internationally recognised as the premier organisation for clinical research, respected as a key influencer, promoting knowledge and understanding by engaging the healthcare community and the general public.
ICR has been in existence since 1978 and has grown from strength to strength since its initiation. Currently the Institute has 5,000 members.
The objectives of ICR are:
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.